---
title: "Wedbush Reaffirms Their Hold Rating on Apogee Therapeutics (APGE)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295552883.md"
description: "Wedbush analyst David Nierengarten reaffirmed a Hold rating on Apogee Therapeutics (APGE) and set a price target of $135.00. This aligns with the broader analyst consensus, which also rates APGE as a Hold with an average price target of $127.03."
datetime: "2026-08-11T13:55:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295552883.md)
  - [en](https://longbridge.com/en/news/295552883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295552883.md)
generator: "portal-rs"
---

# Wedbush Reaffirms Their Hold Rating on Apogee Therapeutics (APGE)

Wedbush analyst David Nierengarten maintained a Hold rating on Apogee Therapeutics today and set a price target of $135.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Damora Therapeutics, and Apogee Therapeutics. According to TipRanks, Nierengarten has an average return of 23.0% and a 54.93% success rate on recommended stocks. 

Apogee Therapeutics has an analyst consensus of Hold, with a price target consensus of $127.03.

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)
- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)

## Related News & Research

- [Apogee Therapeutics’ Merger Faces Significant Execution Risks, Potential $381 Million Termination Fee and Stock Price Pressure](https://longbridge.com/en/news/295510539.md)
- [Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)](https://longbridge.com/en/news/296711581.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)](https://longbridge.com/en/news/296510282.md)
- [Vise Technologies Inc. Takes $743,000 Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296763264.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**